Production & Manufacturing

WuXi Biologics to establish $60m biologics manufacturing facility in Singapore

PBR Staff Writer Published 23 May 2018

Chinese firm WuXi Biologics has announced a S$80m ($60m) investment to set up an a biologics manufacturing facility in Singapore.

The Singapore Economic Development Board is supporting the development of new facility, which is the firm’s first abroad site in Asia and second site outside of China.

The company’s tenth global drug substance manufacturing facility will create around 150 new jobs in the region.

WuXi Biologics chairman Ge Li said: “Singapore is acknowledged as a leader in the biopharmaceutical industry. The new site plays a key role in WuXi Biologics’ global biomanufacturing network to ensure that biologics are manufactured at the highest quality and with a robust supply chain to benefit patients worldwide.”

Wuxi will deploy single-use bioreactors at the next-generation facility, and is designed to support continuous bioprocessing.

The Singapore facility is said to be the firm’s first site to implement next-generation manufacturing technology in Asia outside of China.

The company will install up to 4,500L bioreactor capacity at the facility, including two 2,000L traditional fed-batch and one 500L perfusion based continuous processing.

WuXi’s new facility will engage in both clinical and small volume commercial production. It will also include an early-stage bioprocess development lab.

WuXi Biologics CEO Chris Chen said: “We are all very excited to initiate our first overseas Asian site in Singapore to enable local companies and expedite biologics development in Asia.

“We are committed to becoming the most comprehensive capability and technology platform in the global biologics industry to enable both local and global partners.”

Based in Wuxi city of Jiangsu province, WuXi Biologics offers end-to-end solutions, which will help organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.

The company provides global customers with integrated discovery-to-drug product platform, comprehensive quality system, project management team, CMC documentation support, regulatory assistance and support, as well as integrated IT and project management systems.